The University of Texas MD Anderson Cancer Center received a $251,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to develop a novel cell-based therapy targeting Candida infections. The project aims to generate chimeric antigen receptor (CAR) constructs in T cells and macrophages to provide long-term protection against opportunistic Candida infections, without disrupting the normal gut microbiome. As a sub-award, the University of Texas Health Science Center at Houston will assist with experimental design, data analysis, and establishing relevant host-pathogen interaction assays to support the project. The expected outcomes include laying the groundwork to control other opportunistic pathogens and provide long-term benefits to immunocompromised patients susceptible to Candida infections.
Generated 3/4/25, 8:25 AM